Ferumoxytol增强MR血管成像与双功能超声在血液透析动静脉瘘术前血管测绘中的对比
前瞻性比较研究纳入59例慢性肾病患者,在动静脉瘘术前分别行Ferumoxytol增强MR血管成像与双功能超声血管测绘。Ferumoxytol增强MR血管成像读片者间和读片者内重复性优秀(ICC 0.84-0.99),除显示15处中心血管狭窄外,还识别出双功能超声未识别的外周动脉病变,并对动静脉瘘手术结局的预测优于双功能超声。
要点
- Ferumoxytol增强MR血管成像可显示双功能超声无法评估的中心血管狭窄,本研究共显示15处中心血管狭窄。
- Ferumoxytol增强MR血管成像判定236个动脉节段中88个(37%)不适合造瘘,双功能超声为61个(26%)(P = .01)。
- Ferumoxytol增强MR血管成像对动静脉瘘成功的预测独立于年龄和性别,纳入中心血管时OR 6.5(95%CI 1.7, 25; P = .006),排除中心血管时OR 4.6(95%CI 1.3, 17; P = .02)。
关键影像表现/征象
- Ferumoxytol增强MR血管成像显示15处中心血管狭窄。
- Ferumoxytol增强MR血管成像将236个受检动脉节段中的88个(37%)判定为不适合造瘘,双功能超声为61个(26%)(P = .01)。
- Ferumoxytol增强MR血管成像显示双功能超声未识别的外周动脉病变。
诊断标准与关键数值
- Ferumoxytol增强MR血管成像所有评估变量的读片者间和读片者内重复性ICC为0.84-0.99。
- 共创建51个动静脉瘘,其中24个(47%)成功。
- 基于公认的动静脉瘘创建标准开发算法,依据影像表现预测动静脉瘘结局。
- 多变量回归模型以动静脉瘘成功为因变量,年龄、性别及双功能超声或Ferumoxytol增强MR血管成像表现为自变量;Ferumoxytol增强MR血管成像独立预测动静脉瘘成功:纳入中心血管模型OR 6.5(95%CI 1.7, 25; P = .006),排除中心血管模型OR 4.6(95%CI 1.3, 17; P = .02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Duplex US is performed routinely for vascular mapping prior to arteriovenous fistula (AVF) creation for hemodialysis but cannot demonstrate the central vasculature. Ferumoxytol, an iron oxide nanoparticle, provides an alternative to gadolinium contrast material for MR angiography for safe use in chronic kidney disease (CKD). Purpose To assess the clinical utility of ferumoxytol-enhanced MR angiography compared with duplex US for vascular mapping before upper limb AVF creation in participants with CKD. Materials and Methods In a prospective comparative study (ClinicalTrials.gov: NCT02997046) from December 2016 to August 2018, participants with CKD underwent ferumoxytol-enhanced MR angiography and duplex US. Two independent readers evaluated vessels for diameter, stenosis or occlusion, arterial disease, and central stenosis. Intraclass correlation coefficients (ICCs) and Bland-Altman plots were used to assess intra- and interreader variability. On the basis of accepted standards for AVF creation, an algorithm was developed to predict AVF outcome based on imaging findings. Multivariable regression models used AVF success as the dependent variable and age, sex, and duplex US or ferumoxytol-enhanced MR angiography findings as independent variables. Results Fifty-nine participants with CKD (mean age, 59 years ± 13 [standard deviation]; 30 women) were evaluated. A total of 51 fistulas were created, of which 24 (47%) were successful. Ferumoxytol-enhanced MR angiography showed excellent inter- and intrareader repeatability (ICC, 0.84-0.99) for all variables assessed. In addition to revealing 15 central vasculature stenoses, ferumoxytol-enhanced MR angiography resulted in characterization of 88 of 236 (37%) of the arterial sections examined as unsuitable for AVF creation compared with 61 of 236 (26%) sections with duplex US (P = .01). Ferumoxytol-enhanced MR angiography independently predicted AVF success in models including (odds ratio, 6.5; 95% confidence interval: 1.7, 25; P = .006) and those excluding (odds ratio, 4.6; 95% confidence interval: 1.3, 17; P = .02) the central vasculature. Conclusion In addition to enabling identification of central vessel pathologic features, ferumoxytol-enhanced MR angiography revealed peripheral arterial disease not recognized with duplex US and was more predictive than duplex US of the outcome of arteriovenous fistula surgery. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Finn in this issue.
引用
- Stoumpos S, Tan A, Hall Barrientos P, et al. Ferumoxytol MR Angiography versus Duplex US for Vascular Mapping before Arteriovenous Fistula Surgery for Hemodialysis. Radiology. 2020. PMID: 32692301. doi:10.1148/radiol.2020200069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。